Difference between revisions of "Loncastuximab tesirine (Zynlonta)"
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/loncastuximab-tesirine NCI Drug Dictionary]: An antibody-drug conjugate (ADC...") |
m (→Also known as) |
||
| Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ADCT-402 | *'''Code name:''' ADCT-402 | ||
| + | *'''Generic name:''' loncastuximab tesirine-lpyl | ||
| + | *'''Brand name:''' Zynlonta | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 19:09, 24 April 2021
Mechanism of action
From the NCI Drug Dictionary: An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells.
Diseases in which it is used
History of changes in FDA indication
- 4/23/2021: Approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
Also known as
- Code name: ADCT-402
- Generic name: loncastuximab tesirine-lpyl
- Brand name: Zynlonta